Top San Francisco Bay Area, CA Biotech Companies (311)
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the development of breakthrough products. Help us bring modern software to modern science. We’re on Team Science We believe in the promise of science and the teamwork required to fulfill that promise. Whether your background is in science, engineering, business, or another field, you’re on Team Science if you believe in the power of science to solve the world’s most pressing problems.
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
Insitro is a data-driven drug discovery and development company.
Pendulum is committed to developing novel interventions that target the human microbiome to improve the lives of patients suffering from a variety of diseases. Our targeted formulations of natural bacterial strains help to rebalance the microbiome which restores and improve one’s health.
Pivot Bio is a sustainable agriculture company delivering farmers patented crop nutrition technologies that harness the power of nature to reliably and productively grow the food the world needs in the face of increasing volatility.
At BioNex Solutions, we develop instrumentation and integrated systems that solve the most demanding applications in biopharmaceutical, biotech, and academic research. Our hardware and software philosophy is to design single-purpose, high performance modules, and integrate them to produce the desired functionality. Rather than push a single, generalized product that tries to meet the needs of every customer, we prefer to tailor our control software to each customers' needs to make operation as simple as possible. ISO 9001:2008 & ISO 13485:2003 Certified
Totus Medicines is applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com.
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies. Immune-Onc’s lead program IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), is being developed to treat acute myeloid leukemia (AML) and other cancers. IO-202 is the first T-cell activator for AML. In September 2020, Immune-Onc initiated a Phase I trial evaluating IO-202 in blood cancers, AML and chronic myelomonocytic leukemia (CMML). The company plans to evaluate IO-202 in solid tumors and in other forms of blood cancer in the near future. In addition to IO-202, Immune-Onc’s pipeline includes IO-108, an antibody targeting LILRB2 (also known as ILT4) in the IND-enabling stage of development. Additional preclinical candidates focused on myeloid checkpoints include an anti-LAIR1 antibody and multiple undisclosed programs for solid tumors and hematologic malignancies. For more information, please visit www.immune-onc.com.
Aditum is the Latin word for "access," and our mission is to give patients access to medicines that may not otherwise be developed. Aditum Bio is a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum Bio brings together unmatched scientific and domain expertise, combined with operational capabilities. Our agile operating model enables rapid company formation, planning and execution for a new model of drug development . We target clinic-ready therapies to help underserved patient populations, rapidly forming companies and staffing them with medical and scientific experts. Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum Bio currently manages a broad portfolio of clinical stage companies.
Project Ronin is on a mission to transform cancer care by helping doctors and patients make better-informed decisions about treatment. Our cancer intelligence software provides all the information physicians need, in one place, to assess patient care options and take action. We use predictive technology to present doctors with different scenarios that can help them further optimize care. And, we bring the patient voice to the physician by allowing patients to report symptoms, side effects, and disease progression information via our mobile app, enabling real-time symptom management and true shared decision making with the care team. Project Ronin was founded by Dave Hodgson, one of the world’s leading architects of smart technology for doctors and patients; renowned cancer expert Dr. David Agus; serial health entrepreneur Rowan Chapman, PhD; and tech visionary Larry Ellison. We’re hiring!
Calico is an Alphabet-founded research and development company whose mission is to harness advanced technologies and model systems to increase our understanding of the biology that controls human aging. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Calico’s highly innovative technology labs, its commitment to curiosity-driven discovery science and, with academic and industry partners, its vibrant drug-development pipeline together create an inspiring and exciting place to catalyze and enable medical breakthroughs. Calico is currently seeking exceptional candidates who share our passion for understanding the science of aging and developing therapeutics to address age-related diseases. Explore with us! https://www.calicolabs.com/careers
Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation, with over 1000 staff from 53 nationalities, including 900 scientists working on drug discovery programmes. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
.png){kind=logo}
The Tivic Health team is dedicated to developing advanced bioelectronic solutions that treat disease, increase wellness and improve lives. Our initial focus is delivering sinus pain relief. ClearUP is new alternative for temporary relief of sinus pain. www.tivichealth.com Currently, the most recommended treatment for those experiencing recurring sinus pain is daily flushing of the nose with salt water. We believe people should have access to relief without pills, sprays and flushes.
Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data
Ascend is an end-to-end gene therapy development partner with deep expertise in gene therapy development and commercialization. We offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together!
HALO Precision Diagnostics™ changes patient lives and outcomes through early detection of the leading causes of death with precision diagnostics. We accomplish this with a personalized diagnostic ensemble including advanced imaging, genomics, non-invasive liquid biomarkers, and community-based data at scale combined with deep learning algorithms. By optimizing all these solutions under the HALO Diagnostics platform, we provide rapid, precise, actionable results to enable life-changing treatments by physicians for their patients.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Work Your Passion. Live Your Purpose.
